Basic and clinical studies on cefclidin

Yoshiro Sawae, Kaoru Okada, Kouji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Katsuhiko Eguchi, Yoshiyuki Niho

Research output: Contribution to journalArticle

Abstract

Basic and clinical studies were conducted on cefclidin (CFCL) which is a newly developed intravenously injectable cephalosporin. The results were as follows. 1) The MICs of CFCL and the control drugs, i:e., cefotaxime (CTX), ceftazidime (CAZ) and cefoperazone (CPZ) against various clinical isolates were determined in accordance with the standard method established by the Japan Society of Chemotherapy. The MIC90s of CFCL for Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus vulgaris, Proteus mirabilis, Citrobacter spp. and Pseudomonas aeruginosa were 12.5, > 100, 0.20, 0.20, 0.78, 0.20 1.56, 0.39, 0.39, 3.13 and 12.5 µg/ml, respectively. The antibacterial activity of CFCL against S.aureus was compatible to that of CAZ but inferior to those of CTX and CPZ. The antibacterial activity of CFCL against E. cloacae and Citrobacter spp. was superior to the activities of CTX, CAZ and CPZ. In particular, the antibacterial activity of CFCL against P. aeruginosa was distinctly more potent than those of CTX, CAZ and CPZ. 2) CFCL was used in the treatment of 5 patients (3 patients with pneumonia, 1 with pulmonary abscess, and 1 with acute bronchitis). CFCL was injected i.v. in a daily dosage of 2.0g-4.0g for 9-21 days, and the clinical response was good in 4 cases and poor in 1. P. aeruginosa and Bacteroides intermedins were isolated as causative bacteria and P. aeruginosa was eradicated, but B intermedins persisted. Neither adverse reactions nor abnormal laboratory change were observed.

Original languageEnglish
Pages (from-to)360-364
Number of pages5
JournalChemotherapy
Volume40
DOIs
Publication statusPublished - Jan 1 1992

Fingerprint

Cefoperazone
Ceftazidime
Cefotaxime
Pseudomonas aeruginosa
Citrobacter
Enterobacter cloacae
Proteus vulgaris
Enterobacter aerogenes
Lung Abscess
Proteus mirabilis
Serratia marcescens
Bacteroides
Clinical Studies
cefclidin
Bronchitis
Enterococcus faecalis
Drug and Narcotic Control
Klebsiella pneumoniae
Cephalosporins
Staphylococcus aureus

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Sawae, Y., Okada, K., Takaki, K., Shimono, N., Misumi, H., Eguchi, K., & Niho, Y. (1992). Basic and clinical studies on cefclidin. Chemotherapy, 40, 360-364. https://doi.org/10.11250/chemotherapy1953.40.Supplement4_360

Basic and clinical studies on cefclidin. / Sawae, Yoshiro; Okada, Kaoru; Takaki, Kouji; Shimono, Nobuyuki; Misumi, Hiroyasu; Eguchi, Katsuhiko; Niho, Yoshiyuki.

In: Chemotherapy, Vol. 40, 01.01.1992, p. 360-364.

Research output: Contribution to journalArticle

Sawae, Y, Okada, K, Takaki, K, Shimono, N, Misumi, H, Eguchi, K & Niho, Y 1992, 'Basic and clinical studies on cefclidin', Chemotherapy, vol. 40, pp. 360-364. https://doi.org/10.11250/chemotherapy1953.40.Supplement4_360
Sawae, Yoshiro ; Okada, Kaoru ; Takaki, Kouji ; Shimono, Nobuyuki ; Misumi, Hiroyasu ; Eguchi, Katsuhiko ; Niho, Yoshiyuki. / Basic and clinical studies on cefclidin. In: Chemotherapy. 1992 ; Vol. 40. pp. 360-364.
@article{510ac41459a146bbb18fb9fd949d9c08,
title = "Basic and clinical studies on cefclidin",
abstract = "Basic and clinical studies were conducted on cefclidin (CFCL) which is a newly developed intravenously injectable cephalosporin. The results were as follows. 1) The MICs of CFCL and the control drugs, i:e., cefotaxime (CTX), ceftazidime (CAZ) and cefoperazone (CPZ) against various clinical isolates were determined in accordance with the standard method established by the Japan Society of Chemotherapy. The MIC90s of CFCL for Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus vulgaris, Proteus mirabilis, Citrobacter spp. and Pseudomonas aeruginosa were 12.5, > 100, 0.20, 0.20, 0.78, 0.20 1.56, 0.39, 0.39, 3.13 and 12.5 µg/ml, respectively. The antibacterial activity of CFCL against S.aureus was compatible to that of CAZ but inferior to those of CTX and CPZ. The antibacterial activity of CFCL against E. cloacae and Citrobacter spp. was superior to the activities of CTX, CAZ and CPZ. In particular, the antibacterial activity of CFCL against P. aeruginosa was distinctly more potent than those of CTX, CAZ and CPZ. 2) CFCL was used in the treatment of 5 patients (3 patients with pneumonia, 1 with pulmonary abscess, and 1 with acute bronchitis). CFCL was injected i.v. in a daily dosage of 2.0g-4.0g for 9-21 days, and the clinical response was good in 4 cases and poor in 1. P. aeruginosa and Bacteroides intermedins were isolated as causative bacteria and P. aeruginosa was eradicated, but B intermedins persisted. Neither adverse reactions nor abnormal laboratory change were observed.",
author = "Yoshiro Sawae and Kaoru Okada and Kouji Takaki and Nobuyuki Shimono and Hiroyasu Misumi and Katsuhiko Eguchi and Yoshiyuki Niho",
year = "1992",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.40.Supplement4_360",
language = "English",
volume = "40",
pages = "360--364",
journal = "CHEMOTHERAPY",
issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on cefclidin

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Takaki, Kouji

AU - Shimono, Nobuyuki

AU - Misumi, Hiroyasu

AU - Eguchi, Katsuhiko

AU - Niho, Yoshiyuki

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Basic and clinical studies were conducted on cefclidin (CFCL) which is a newly developed intravenously injectable cephalosporin. The results were as follows. 1) The MICs of CFCL and the control drugs, i:e., cefotaxime (CTX), ceftazidime (CAZ) and cefoperazone (CPZ) against various clinical isolates were determined in accordance with the standard method established by the Japan Society of Chemotherapy. The MIC90s of CFCL for Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus vulgaris, Proteus mirabilis, Citrobacter spp. and Pseudomonas aeruginosa were 12.5, > 100, 0.20, 0.20, 0.78, 0.20 1.56, 0.39, 0.39, 3.13 and 12.5 µg/ml, respectively. The antibacterial activity of CFCL against S.aureus was compatible to that of CAZ but inferior to those of CTX and CPZ. The antibacterial activity of CFCL against E. cloacae and Citrobacter spp. was superior to the activities of CTX, CAZ and CPZ. In particular, the antibacterial activity of CFCL against P. aeruginosa was distinctly more potent than those of CTX, CAZ and CPZ. 2) CFCL was used in the treatment of 5 patients (3 patients with pneumonia, 1 with pulmonary abscess, and 1 with acute bronchitis). CFCL was injected i.v. in a daily dosage of 2.0g-4.0g for 9-21 days, and the clinical response was good in 4 cases and poor in 1. P. aeruginosa and Bacteroides intermedins were isolated as causative bacteria and P. aeruginosa was eradicated, but B intermedins persisted. Neither adverse reactions nor abnormal laboratory change were observed.

AB - Basic and clinical studies were conducted on cefclidin (CFCL) which is a newly developed intravenously injectable cephalosporin. The results were as follows. 1) The MICs of CFCL and the control drugs, i:e., cefotaxime (CTX), ceftazidime (CAZ) and cefoperazone (CPZ) against various clinical isolates were determined in accordance with the standard method established by the Japan Society of Chemotherapy. The MIC90s of CFCL for Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus vulgaris, Proteus mirabilis, Citrobacter spp. and Pseudomonas aeruginosa were 12.5, > 100, 0.20, 0.20, 0.78, 0.20 1.56, 0.39, 0.39, 3.13 and 12.5 µg/ml, respectively. The antibacterial activity of CFCL against S.aureus was compatible to that of CAZ but inferior to those of CTX and CPZ. The antibacterial activity of CFCL against E. cloacae and Citrobacter spp. was superior to the activities of CTX, CAZ and CPZ. In particular, the antibacterial activity of CFCL against P. aeruginosa was distinctly more potent than those of CTX, CAZ and CPZ. 2) CFCL was used in the treatment of 5 patients (3 patients with pneumonia, 1 with pulmonary abscess, and 1 with acute bronchitis). CFCL was injected i.v. in a daily dosage of 2.0g-4.0g for 9-21 days, and the clinical response was good in 4 cases and poor in 1. P. aeruginosa and Bacteroides intermedins were isolated as causative bacteria and P. aeruginosa was eradicated, but B intermedins persisted. Neither adverse reactions nor abnormal laboratory change were observed.

UR - http://www.scopus.com/inward/record.url?scp=0026474428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026474428&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.Supplement4_360

DO - 10.11250/chemotherapy1953.40.Supplement4_360

M3 - Article

AN - SCOPUS:0026474428

VL - 40

SP - 360

EP - 364

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -